Navigation Links
Automated Sequence Capture for Next-Generation Sequencing Paves the Way for Personalized Medicine
Date:3/16/2009

HybSelect(TM) first to provide high coverage and megabase capacity for the next generation sequencing community

LEXINGTON, Mass. and HEIDELBERG, Germany, March 16 /PRNewswire/ -- febit today announced the official launch of its new sequence capture technology HybSelect. In several biomedical studies of early access customers over the past months, HybSelect demonstrated superb enrichment factors and deep sequencing coverage for a broad range of human genes and genomic regions. As the first sequence capture technology combining outstanding enrichment and walk-away convenience, HybSelect opens up new opportunities in biomarker discovery and the development of personalized medicine.

Declining costs and dramatically higher sequencing output has distinguished the fast-paced genomics market since 2003. Sequencing a human genome, a project that required years and billions of USD, is now feasible in weeks for thousands of USD. Nevertheless, conducting statistically relevant biomedical studies with deep sequencing of patient samples is still prohibitively expensive and inefficient. HybSelect effectively scales next generation sequencing to the needs of biomedical research and discovery by enabling large scale studies.

The accessibility and enormous capacity of the next generation sequencers have triggered a heightened demand for sequence capture technologies amongst geneticists: targeted re-sequencing of medically-relevant genome loci will greatly enhance the understanding of health and disease in crucial areas such as cancer and Alzheimer's disease. The outcomes of such studies are significant in that they will allow improved diagnostics and targeted applications of medical agents.

"HybSelect even enables large scale targeted re-sequencing studies because of the high degree of automation combined with the power to detect genetically relevant information in the genome with high efficiency, which can not be met by PCR, or other methods on the market. The fully automated HybSelect technology will compel adoption in several ways: short hands-on time (minutes instead of hours), a high degree of reproducibility, and unmatched parallelism in hybselecting several genomic samples at a time," said Peer Staehler, CSO of febit, summarizing the advances of febit's latest product.

The proof of concept has been positively confirmed by early access customers. Dr. Matthew Huentelman, an investigator and lead collaborator at the Translational Genomics Research Institute (TGen) in Phoenix, AZ, was one of the first researchers to use HybSelect. His laboratory uses state-of-the-art techniques to pin-point differences in genes and pathways that contribute to the development and progression of Alzheimer's disease. "We are really excited about the high enrichment factor and the depth of coverage of the targeted sequences that can be achieved using HybSelect from febit. The short hands-on time and ease of use reinforce our intentions to use this new technology for further studies," said Dr. Huentelman.

HybSelect will be also employed in the newly developed Biomarker Discovery Center Heidelberg for the detection of novel tumor markers. Within the European READNA-consortium (REvolutionary Approaches and Devices for Nucleic Acid analysis) HybSelect will support the selection and enrichment of specific gene loci for Next Generation Sequencers.

The new technology is available as a protocol for febit's Geniom RT Analyzer, or as a full service including Next-Gen sequencing from febit. HybSelect is optimized for the Illumina GAII sequencing system, and will be available for other sequencing platforms soon.

HybSelect will be presented at CHI's Conference on Next-Generation Sequencing on March 17-19, 2009 in San Diego, CA. To learn more about febit's new HybSelect technology the febit product launch offers a webinar on March 25, 2009 (11:00 am EDT, 4:00 pm CET).

About febit

febit develops, produces and markets flexible automated solutions for enabling biochip applications in Life Sciences. febit's product portfolio includes various instruments, optimized assays, and bioanalytical services, complemented by bioinformatics software and consulting.

For its main applications, HybSelect -- febit's innovative DNA capture method for Next-Generation-Sequencing -- and protein-coding or non-coding transcriptome profiling, the highly advanced microfluidics of the patented Geniom Biochip offers the highest degree of automation, flexibility and efficiency available.

For more information please visit: www.febit.com

            Contact: febit group, Eva Sterzel, eva.sterzel@febit.com,
                                +49 (0)6221 6510-300
                        Russo Partners, Martina Schwarzkopf,
            martina.schwarzkopf@russopartnersllc.com, +1 212 845-4292


'/>"/>
SOURCE febit
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Introduces Zephyr Genomics Workstation for Automated Liquid Handling
2. T-System Releases The T SystemEV(R) 2.6.3, Featuring New Meds/Allergies Notification, Automated Charge Capture
3. Xceed Ziplex(R) System for Automated Gene-Expression Analysis Wins 2008 R&D 100 Award
4. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
5. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
6. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
7. Xceed Molecular Features Ziplex(R) Automated Gene-Expression System at the Biomarker World Congress, Booth 16
8. Mercy Medical Center Completes Beta Studies for Integrated Hematology and Automated Diabetes Testing Solution
9. diaDexus Selects Fisher HealthCare to Sell New Automated PLAC(R) Test
10. Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell
11. Microfluidic Systems to Show Automated Biological Agent Detection Technology to U.S. House of Representatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):